Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:535709.
doi: 10.1155/2012/535709. Epub 2012 Feb 16.

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms

Mar Bellido  1 , Peter A W Te Boekhorst
Affiliations

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms

Mar Bellido et al. Adv Hematol. 2012.

Abstract

JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms. As a consequence, JAK2 inhibitors have been designed to suppress the cytokine signalling cascade caused by the constitutive activation of JAK2. In clinical trials, JAK2 inhibitors are efficient in decreasing spleen size, controlling clinical symptoms, and improving quality of life in patients with myeloproliferative neoplasms. However, JAK2 inhibitors are unable to target uncommitted hematopoietic progenitors responsible of the initiation of the myeloproliferative disease. It is expected that, in order to cure the myeloproliferative disease, JAK2 inhibitors should be combined with other drugs to target simultaneously different pathways and to target the initiator hematopoietic cell population in myeloproliferative disorders. Taking advantage of the inhibition of the cytokine cascade of JAK2 inhibitors, these compounds are going to be used not only to treat patients with hematological neoplasms but may also be beneficial to treat patients with rheumatoid arthritis or other inflammatory diseases.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Bennett M, Stroncek DF. Recent advances in the bcr-abl negative chronic myeloproliferative diseases. Journal of Translational Medicine. 2006;4, article 41 - PMC - PubMed
    1. Stoddart A, Dykstra ML, Brown BK, Song W, Pierce SK, Brodsky FM. Lipid rafts unite signaling cascades with clathrin to regulate BCR internalization. Immunity. 2002;17(4):451–462. - PubMed
    1. Duran I, Hotté SJ, Hirte H, et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clinical Cancer Research. 2007;13(16):4849–4857. - PubMed
    1. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitivetyrosine kinases. Clinical Cancer Research. 2008;14(9):2717–2725. - PubMed
    1. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. The New England Journal of Medicine. 2010;363(14):1303–1312. - PubMed